BBHC
PTCT icon

Brown Brothers Harriman & Co’s PTC Therapeutics PTCT Stock Holding History

Brown Brothers Harriman & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$47 – 1199
2021
Q1 		$47 Buy
+1,000
New +$59.4K ﹤0.01% 655

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Brown Brothers Harriman & Co's PTCT Position: Q2 2021 in Review

Brown Brothers Harriman & Co sold out of PTC Therapeutics (PTCT) in Q2 2021, closing a stake of 1,000 shares — an estimated $47 sold.

Brown Brothers Harriman & Co first reported a position in PTCT in Q1 2021 and held it in 1 quarter. The position peaked at $47 in Q1 2021. 182 funds tracked by Wall St. Rank hold PTCT as of Q2 2021.

  • Brown Brothers Harriman & Co reported no remaining PTC Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 1,000 PTC Therapeutics shares in Q2 2021, an estimated $47.
  • Brown Brothers Harriman & Co first reported a position in PTC Therapeutics in Q1 2021 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's PTC Therapeutics position peaked at $47 in Q1 2021.
  • 182 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2021, filed 13 Aug 2021.